Oruka Therapeutics Files Q3 2024 10-Q Report
Ticker: ORKA · Form: 10-Q · Filed: Nov 13, 2024 · CIK: 907654
| Field | Detail |
|---|---|
| Company | Oruka Therapeutics, Inc. (ORKA) |
| Form Type | 10-Q |
| Filed Date | Nov 13, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, quarterly-report, biotech
TL;DR
Oruka Therapeutics filed its Q3 10-Q. Check financials.
AI Summary
Oruka Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2024. The company, formerly known as ARCA biopharma, Inc., NUVELO INC, and HYSEQ INC, is incorporated in Delaware and headquartered in Menlo Park, California. The filing details its financial performance and business operations for the specified quarter.
Why It Matters
This filing provides investors and analysts with an update on Oruka Therapeutics' financial health and operational progress during the third quarter of 2024.
Risk Assessment
Risk Level: low — This is a routine quarterly filing providing standard financial and operational information.
Key Players & Entities
- Oruka Therapeutics, Inc. (company) — Registrant
- September 30, 2024 (date) — Quarterly period end date
- ARCA biopharma, Inc. (company) — Former company name
- NUVELO INC (company) — Former company name
- HYSEQ INC (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Menlo Park, CA (location) — Business address city and state
FAQ
What is the filing type and period covered?
The filing is a Form 10-Q, a quarterly report, for the period ended September 30, 2024.
What is the company's official name and ticker symbol?
The company's official name is Oruka Therapeutics, Inc. The filing does not explicitly state a ticker symbol, but the SEC file number is 000-22873.
Where is Oruka Therapeutics, Inc. incorporated and headquartered?
The company is incorporated in Delaware and its business address is in Menlo Park, CA.
Has the company undergone name changes in the past?
Yes, Oruka Therapeutics, Inc. was formerly known as ARCA biopharma, Inc., NUVELO INC, and HYSEQ INC.
What is the Standard Industrial Classification (SIC) code for Oruka Therapeutics?
The SIC code listed is 2835, which corresponds to IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.
Filing Stats: 4,481 words · 18 min read · ~15 pages · Grade level 17.6 · Accepted 2024-11-13 16:01:47
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 per share ORKA The Nasdaq Global Market
Filing Documents
- ea0216929-10q_oruka.htm (10-Q) — 1119KB
- ea021692901ex10-4_oruka.htm (EX-10.4) — 98KB
- ea021692901ex31-1_oruka.htm (EX-31.1) — 10KB
- ea021692901ex31-2_oruka.htm (EX-31.2) — 10KB
- ea021692901ex32-1_oruka.htm (EX-32.1) — 6KB
- 0001213900-24-097443.txt ( ) — 6095KB
- orka-20240930.xsd (EX-101.SCH) — 66KB
- orka-20240930_cal.xml (EX-101.CAL) — 31KB
- orka-20240930_def.xml (EX-101.DEF) — 319KB
- orka-20240930_lab.xml (EX-101.LAB) — 537KB
- orka-20240930_pre.xml (EX-101.PRE) — 329KB
- ea0216929-10q_oruka_htm.xml (XML) — 567KB
Financial Information
PART I. Financial Information Item 1.
Financial Statements (Unaudited)
Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Comprehensive Loss 2 Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) 3 Condensed Consolidated Statement of Cash Flows 4 Notes to Condensed Consolidated Financial Statements 5 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 34 Item 4.
Controls and Procedures
Controls and Procedures 34
Other Information
PART II. Other Information Item 1.
Legal Proceedings
Legal Proceedings 35 Item 1A.
Risk Factors
Risk Factors 35 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 71 Item 3. Defaults Upon Senior Securities 71 Item 4. Mine Safety Disclosures 71 Item 5. Other Information 71 Item 6. Exhibits 72
Signatures
Signatures 73 i Part I - Financial Information Item 1. Financial Statements ORUKA THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (In thousands, except share and per share data) September 30, 2024 February 6, 2024 Assets Current assets: Cash and cash equivalents $ 410,875 $ — Subscription receivable — 1 Prepaid expenses and other current assets 2,074 — Total current assets 412,949 1 Property and equipment, net 160 — Operating lease right-of-use asset 938 — Other non-current assets 43 — Total assets $ 414,090 $ 1 Liabilities, Convertible Preferred Stock and Stockholders' Equity Current liabilities: Accounts payable $ 2,145 $ — Accrued expenses and other current liabilities 1,710 — Operating lease liability, current 146 — Related party common stock warrant liability 7,681 — Related party accounts payable and other current liabilities 6,357 — Total current liabilities 18,039 — Operating lease liability, non-current 842 — Total liabilities 18,881 — Commitment and contingencies (Note 11) Series A convertible preferred stock, $ 0.0001 par value; no shares and 20,000,000 shares authorized as of September 30, 2024 and February 6, 2024, respectively; no shares issued and outstanding as of September 30, 2024 and February 6, 2024; liquidation preference of $ 0 as of September 30, 2024 and February 6, 2024 — — Series A non-voting convertible preferred stock, $ 0.001 par value; 2,439 and no shares authorized as of September 30, 2024 and February 6, 2024, respectively; 2,439 and no shares issued and outstanding as of September 30, 2024 and February 6, 2024, respectively 52,841 — Stockholders' equity: Series B non-voting convertible preferred stock, $ 0.001 par value; 251,504 and no shares authorized as of September 30, 2024 and February 6, 2024, respectively; 137,138 and no shares issued and outstanding as of Septem